COMPANY
About Us
Senior Management Team
Board of directors
Scientific Advisory Board
Business Development
Main Investors
Contact Us
TECHNOLOGIES
OPTIREACH Technology
Antibody Fragment Technology
PIPELINE
Overview
OCS-01 Diabetic Macular Edema
OCS-01 Post Cataract Surgery Inflammation
OCS-02 Uveitis
OCS-02 Dry Eye
OCS-05 Glaucoma
NEWS
Press releases
Articles
CAREERS
COMPANY
About Us
Senior Management Team
Board of directors
Scientific Advisory Board
Business Development
Main Investors
Contact Us
TECHNOLOGIES
OPTIREACH Technology
Antibody Fragment Technology
PIPELINE
Overview
OCS-01 Diabetic Macular Edema
OCS-01 Post Cataract Surgery Inflammation
OCS-02 Uveitis
OCS-02 Dry Eye
OCS-05 Glaucoma
NEWS
Press releases
Articles
CAREERS
Press Releases 2021
November 12, 2021
Oculis Announces
Patient Dosing in its First Phase 3 with OCS-01
for Diabetic Macular Edema (DIAMOND Study)
October 7, 2021
Oculis
Appoints Dr. Joanne Chang
as Global Chief Medical Officer and
Opens Hong Kong Office
May
11, 2021
Oculis Announces
Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02
, Presented at ARVO 2021
May 04, 2021
Oculis Announces an
Oversubscribed US$57 million Series C
Financing
Press Releases 2021
Press Releases 2020
Press Releases 2019
Press Releases 2018